drugset / Trial / NCT07349472
Pentoxifylline in Patients With Ulcerative Colitis
RandomizedParallel-groupDouble-blindTreatment
Summary
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.
Timeline
- Start
- 2026-01-20
- Primary completion
- 2027-01-20
- Completion
- 2027-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pentoxifylline | Small molecule | 400 mg | — |
| Comparator | Mesalamine | Small molecule | 1 g | — |